SOVREMENNAYA PEDIATRIYA.2016.3(75):85-89; doi10.15574/SP.2016.75.85 

Allergic rhinitis and asthma in children: evaluation of effectiveness of levocetirizine 

Umanets T. R., Lapshin V. F., Matveeva S. U., Pustovalova О. I.

SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev, Ukraine 

The aim of the study was to investigate the efficacy and safety of the drug Cetrilev for treatment children withallergic rhinitisand asthma.

Methods. 60 children aged 6–14 years with persistent allergic rhinitisand asthma were included in this study. All the children were divided into two groups: group 1(32 children) and group 2 (29 children). Group1 of children were given Cetrilev («Euro Lifecare LTD») in addition to the standard treatment, with a dosage of 1 tablet (5 mg) per day for 4 weeks. Children from the comparison group 2 received only the standard treatment. As a standard treatment of Asthma, Montelukast 5 mg was given once daily in the evening. To evaluate the effectiveness of all the children held a score of symptoms of allergic rhinitis and asthma, spirometry, nasal cytology, asthma control testing.

Results. The study have shown that the inclusion of the drug Cetrilev in therapy children with allergic rhinitis and asthma had a positive effect on symptoms such as rhinitis and asthma. Children of the group1had significant regression of symptoms of allergic rhinitis , reduction of inflammatory changes in the mucosa of the upper respiratory tract, improvement of lung function.

Conclusion: Therapeutic effect of the drug Cetrilev is associated with anti-allergic and anti-inflammatory effects. The absence of side effects, good tolerability of this drug can be recommended for its treatment of allergic rhinitis in children of school age with asthma.

Keywords: allergic rhinitis,asthma, treatment, levocetirizine.

REFERENCES

1. Antipkіn YG, Lapshyn VF, Umanets TR. 2010. Clinical guidelines for the diagnosis and treatment of asthma in children. Health Ukraine. 3(14): 39—41.

2. Romanyuk LI. 2013 Allergic rhinitis as a comorbid condition of asthma. Asthma and allergy. 2: 62—65.

3. Brozek JL, Bousquet J, Baena-Cagnani CE et al. 2010. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision. J Allergy Clin Immunol. 126: 466—76. http://dx.doi.org/10.1016/j.jaci.2010.06.047; PMid:20816182

4. Globalstrategy for asthma management and prevention. National institutes of health. National Heart, lung and Blood Institute. Revised 2016. http://www.ginasthma.org.

5. Hansen TE, Evjenth B, Holt J. 2013. Increasing prevalence of asthma, allergic rhinoconjunctivitis and eczema among schoolchildren: three surveys during the period 1985–2008. Foundation Acta Pediatrica. 102: 47—52. http://dx.doi.org/10.1111/apa.12030; PMid:22994385

6. Hedlin G, Konradsen J, Bush A. 2012. An update on paediatric asthma. Eur Respir Rev. 21(125): 175—185. http://dx.doi.org/10.1183/09059180.00003212; PMid:22941882

7. Papadopoulos NG, Arakawa H, Carlsen KH et al. 2012. Internationalconsensus on (ICON) pediatric asthma. Allergy. 67; 8: 976—997. http://dx.doi.org/10.1111/j.1398-9995.2012.02865.x; PMid:22702533 PMCid:PMC4442800

8. Obimbo EM, Levin ME. 2013. Allergic rhinitis and asthma — evidence for an association. Current Allergy & Clinical Immunology. 26; 1: 4—7.

9. Valovirta E. 2012. Managing Co-Morbid Asthma With Allergic Rhinitis: Targeting the One-Airway With Leukotriene Receptor Antagonists. WAO Journal. 5: 210—211. http://dx.doi.org/10.1097/wox.0b013e31821d1186; http://dx.doi.org/10.1186/1939-4551-5-s3-s210; http://dx.doi.org/10.1097/1939-4551-5-s3-s210